Profile
Ronald G.
Tompkins is the founder of Cellective Dx Corp.
founded in 2005.
He currently works as a Director at AZTherapies, Inc.
Ronald G. Tompkins active positions
Companies | Position | Start |
---|---|---|
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Director/Board Member | - |
Former positions of Ronald G. Tompkins
Companies | Position | End |
---|---|---|
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | Health Technology |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Ronald G. Tompkins